Five-year postsurgical monitoring of serum p53 antibody for locally advanced esophageal squamous cell carcinoma

Clin J Gastroenterol. 2018 Aug;11(4):278-281. doi: 10.1007/s12328-018-0839-3. Epub 2018 Mar 1.

Abstract

Serum p53 antibody (s-p53-Ab) titers were postoperatively monitored for over 5 years in a 67-year-old man with locally advanced esophageal squamous cell carcinoma. The tumor stage was classified as clinical stage II (cT3N0M0). Serum SCC antigen (s-SCC-Ag; 6.2 ng/mL) and s-p53-Ab (3.83 U/mL) were noted to be positive before surgery. Radical esophagectomy with three-field lymph node dissection was performed without neoadjuvant therapy. Pathological findings of the surgically resected specimens revealed a stage II tumor (pT3N0M0). Postoperatively, the patients did not receive any adjuvant therapy. Although the s-SCC-Ag was found to be negative at 2 months postoperatively, s-SCC-Ag was found to be six times positive despite no signs of recurrence. The s-p53-Ab titers constantly decreased to less than the cutoff value at 6 months postoperatively and continuously decreased over 5 years postoperatively. Finally, s-p53-Ab titers became less than the detection limit value at 60 months postoperatively. No recurrence was observed throughout the postoperative course. This case report is the first to describe the five-year monitoring of postoperative changes in s-p53-Ab titers in a patient with locally advanced esophageal squamous cell carcinoma without recurrence. s-p53-Ab titers seemed to be more useful than s-SCC-Ag for disease monitoring in this case.

Keywords: Antibody titer; Esophageal squamous cell carcinoma; Monitoring; Serum p53 antibody.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood*
  • Carcinoma, Squamous Cell / blood*
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / surgery*
  • Esophageal Neoplasms / blood*
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / surgery*
  • Esophageal Squamous Cell Carcinoma
  • Esophagectomy
  • Follow-Up Studies
  • Humans
  • Lymph Node Excision
  • Male
  • Neoplasm Staging
  • Tumor Suppressor Protein p53 / blood*

Substances

  • Biomarkers, Tumor
  • Tumor Suppressor Protein p53